The metabolic health conversation is changing. Prescription GLP-1 drugs continue to dominate headlines. But, beneath that narrative, a quieter and potentially more durable approach is gaining attention throughout the dietary supplement and nutraceutical sectors.
Rather than attempting to replicate hormone activity pharmacologically, formulators and researchers are increasingly focused on supporting the physiological systems that are responsible for endogenous hormone production.
From a pharmacist’s perspective, this shift reflects a broader maturation of the category.
The question is no longer whether GLP-1 matters; it’s how to support its natural release safely, sustainably and in a way that aligns with consumer demand for non-drug solutions.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Nutraceutical Business Review.
Subscribe now Already a subscriber? Sign in here.